TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents
Brief Summary: This study will test an 18-month intervention designed to increase physical activity, reduce sedentary practices and promote healthy diets or reduce tobacco use and exposure among preteens who obtain orthodontic care. Relevance: If successful, this study may inform policies that would promote all specialists (orthodontists, physicians, general dentists) to deliver brief counseling for diet, physical activity, and tobacco prevention.


Options:
A: Arm Label: CBP + PF; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Current Best Practices (CBP) | Arm Label: CBP + PF + P4P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Financial Incentive (P4P), Behavioral: Current Best Practices (CBP) | Arm Label: Current Best Practices (CBP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Current Best Practices (CBP) | Intervention Type: BEHAVIORAL; Name: Audit and performance feedback (PF); Assigned to Arm(s): CBP + PF, CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Financial Incentive (P4P); Assigned to Arm(s): CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Current Best Practices (CBP); Assigned to Arm(s): CBP + PF, CBP + PF + P4P, Current Best Practices (CBP)
B: Arm Label: Obesity prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity Prevention | Arm Label: Tobacco prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Prevention | Intervention Type: BEHAVIORAL; Name: Obesity Prevention; Assigned to Arm(s): Obesity prevention | Intervention Type: BEHAVIORAL; Name: Tobacco Prevention; Assigned to Arm(s): Tobacco prevention
C: Arm Label: Control (Usual care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tobacco Cessation Tool (CATI Tool); Type: EXPERIMENTAL; Interventions: Behavioral: CATI Tool | Intervention Type: BEHAVIORAL; Name: CATI Tool; Assigned to Arm(s): Tobacco Cessation Tool (CATI Tool)
D: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents
Brief Summary: This study will test an 18-month intervention designed to increase physical activity, reduce sedentary practices and promote healthy diets or reduce tobacco use and exposure among preteens who obtain orthodontic care. Relevance: If successful, this study may inform policies that would promote all specialists (orthodontists, physicians, general dentists) to deliver brief counseling for diet, physical activity, and tobacco prevention.


Options:
A: Arm Label: New Moves Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: New Moves | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Moves; Assigned to Arm(s): New Moves Intervention Group
B: Arm Label: Volunteering; Type: EXPERIMENTAL; Interventions: Behavioral: Volunteering | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Volunteering; Assigned to Arm(s): Volunteering
C: Arm Label: Obesity prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity Prevention | Arm Label: Tobacco prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Prevention | Intervention Type: BEHAVIORAL; Name: Obesity Prevention; Assigned to Arm(s): Obesity prevention | Intervention Type: BEHAVIORAL; Name: Tobacco Prevention; Assigned to Arm(s): Tobacco prevention
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Improve access to the school breakfast program | Arm Label: Comparison arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improve access to the school breakfast program; Assigned to Arm(s): Intervention arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy : Analysis of Risk Factors and Association With Genetic Polymorphisms
Brief Summary: The treatment of postoperative pain continues to be inadequate in the investigators practice setting.

Inadequate pain treatment not only contributes to postoperative complications in the short term but can also be a factor that favors the development of chronic postoperative pain and diminishes long-term quality of life. Risk factors that can lead to a transition to chronic pain need to be analyzed.


Options:
A: Arm Label: Patients who had inguinal herniorraphy.; Type: N/A; Interventions: Procedure: Inguinal herniorraphy. | Arm Label: Patients who had hysterectomy.; Type: N/A; Interventions: Procedure: Hysterectomy. | Arm Label: Patients who had thoracotomy.; Type: N/A; Interventions: Procedure: Thoracotomy . | Intervention Type: PROCEDURE; Name: Inguinal herniorraphy.; Assigned to Arm(s): Patients who had inguinal herniorraphy. | Intervention Type: PROCEDURE; Name: Hysterectomy.; Assigned to Arm(s): Patients who had hysterectomy. | Intervention Type: PROCEDURE; Name: Thoracotomy .; Assigned to Arm(s): Patients who had thoracotomy.
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
C: Arm Label: ropivacaine + methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: ropivacaine 0.2%, Drug: Methylprednisolone 1mg/kg | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline 0.9% | Intervention Type: DRUG; Name: ropivacaine 0.2%; Assigned to Arm(s): ropivacaine + methylprednisolone | Intervention Type: DRUG; Name: Methylprednisolone 1mg/kg; Assigned to Arm(s): ropivacaine + methylprednisolone | Intervention Type: DRUG; Name: saline 0.9%; Assigned to Arm(s): saline
D: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy : Analysis of Risk Factors and Association With Genetic Polymorphisms
Brief Summary: The treatment of postoperative pain continues to be inadequate in the investigators practice setting.

Inadequate pain treatment not only contributes to postoperative complications in the short term but can also be a factor that favors the development of chronic postoperative pain and diminishes long-term quality of life. Risk factors that can lead to a transition to chronic pain need to be analyzed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
B: Arm Label: Patients who had inguinal herniorraphy.; Type: N/A; Interventions: Procedure: Inguinal herniorraphy. | Arm Label: Patients who had hysterectomy.; Type: N/A; Interventions: Procedure: Hysterectomy. | Arm Label: Patients who had thoracotomy.; Type: N/A; Interventions: Procedure: Thoracotomy . | Intervention Type: PROCEDURE; Name: Inguinal herniorraphy.; Assigned to Arm(s): Patients who had inguinal herniorraphy. | Intervention Type: PROCEDURE; Name: Hysterectomy.; Assigned to Arm(s): Patients who had hysterectomy. | Intervention Type: PROCEDURE; Name: Thoracotomy .; Assigned to Arm(s): Patients who had thoracotomy.
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Influences to Prevent Childhood Obesity: An Integrated Research and Outreach Program for Parents of Montana 4-H Youth
Brief Summary: The main goal of this project is to develop, deliver, and assess the efficacy of a parent-centered educational program (4-Health) designed to prevent preteen children from becoming overweight.


Options:
A: Arm Label: 4-Health Educational curriculum; Type: EXPERIMENTAL; Interventions: Behavioral: 4-Health Educational curriculum | Arm Label: Healthy Living Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Living Information | Intervention Type: BEHAVIORAL; Name: 4-Health Educational curriculum; Assigned to Arm(s): 4-Health Educational curriculum | Intervention Type: BEHAVIORAL; Name: Healthy Living Information; Assigned to Arm(s): Healthy Living Information
B: Arm Label: Healthy Buddies Curriculum; Type: EXPERIMENTAL; Interventions: Other: Healthy Buddies Curriculum | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Buddies Curriculum; Assigned to Arm(s): Healthy Buddies Curriculum
C: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
D: Arm Label: Healthy Eating/Physical Activity; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating/Physical Activity | Arm Label: Safety/Injury Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Safety/Injury Prevention | Intervention Type: BEHAVIORAL; Name: Healthy Eating/Physical Activity; Assigned to Arm(s): Healthy Eating/Physical Activity | Intervention Type: BEHAVIORAL; Name: Safety/Injury Prevention; Assigned to Arm(s): Safety/Injury Prevention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Helicobacter Pylori Eradication on the New Tumor Development After Endoscopic Resection of Gastric Tumors
Brief Summary: The purpose of this study is to determine whether Helicobacter pylori eradication could reduce the new tumor development after endoscopic resection of gastric tumor.


Options:
A: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: eradication treatment of Helicobacter pylori infection | Intervention Type: DRUG; Name: eradication treatment of Helicobacter pylori infection; Assigned to Arm(s): treatment group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clarithromycin, Amoxicillin, Omeprazole | Intervention Type: DRUG; Name: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Clarithromycin, Amoxicillin, Omeprazole; Assigned to Arm(s): 2
C: Arm Label: H pylori eradication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Helicobacter pylori eradication | Intervention Type: DRUG; Name: Helicobacter pylori eradication; Assigned to Arm(s): H pylori eradication
D: Arm Label: Group 1:Triple therapy; Type: EXPERIMENTAL; Interventions: Drug: Triple therapy | Arm Label: Group 2:No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Triple therapy; Assigned to Arm(s): Group 1:Triple therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout
Brief Summary: This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.


Options:
A: Arm Label: Febuxostat; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol
B: Arm Label: RDEA3170 2.5 mg, 7.5 mg and 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RDEA3170 2.5 mg, Drug: allopurinol 300 mg | Arm Label: RDEA3170 5 mg, 10 mg and 20 mg; Type: EXPERIMENTAL; Interventions: Drug: RDEA3170 2.5 mg, Drug: allopurinol 300 mg | Intervention Type: DRUG; Name: RDEA3170 2.5 mg; Assigned to Arm(s): RDEA3170 2.5 mg, 7.5 mg and 15 mg, RDEA3170 5 mg, 10 mg and 20 mg | Intervention Type: DRUG; Name: allopurinol 300 mg; Assigned to Arm(s): RDEA3170 2.5 mg, 7.5 mg and 15 mg, RDEA3170 5 mg, 10 mg and 20 mg
C: Arm Label: lesinurad 400 mg + febuxostat 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Febuxostat | Arm Label: lesinurad 200 mg + febuxostat 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Febuxostat | Arm Label: placebo + febuxostat 80 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Febuxostat | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 400 mg + febuxostat 80 mg | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 200 mg + febuxostat 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo + febuxostat 80 mg | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): lesinurad 200 mg + febuxostat 80 mg, lesinurad 400 mg + febuxostat 80 mg, placebo + febuxostat 80 mg
D: Arm Label: Nurse intervention; Type: OTHER; Interventions: Other: Nurse intervention | Arm Label: Standard care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Nurse intervention; Assigned to Arm(s): Nurse intervention | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance
Brief Summary: The investigators will study whether, in young children with acute otitis media (AOM), shortening length of antibiotic treatment as a strategy for reducing antimicrobial resistance provides satisfactory clinical outcome. This is a Phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial in 600 children aged 6 through 23 months comparing the efficacy of consistent reduced-duration antimicrobial treatment (5 days) with that of consistent standard-duration treatment (10 days) for each episode of AOM developing during a single respiratory season (October 1 through May 31).


Options:
A: Arm Label: Amoxicillin-Clavulanate, 10 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin-Clavulanate, 10 days | Arm Label: Amoxicillin-Clavulanate, 5 days; Type: OTHER; Interventions: Drug: Amoxicillin-Clavulanate, 5 days | Intervention Type: DRUG; Name: Amoxicillin-Clavulanate, 10 days; Assigned to Arm(s): Amoxicillin-Clavulanate, 10 days | Intervention Type: DRUG; Name: Amoxicillin-Clavulanate, 5 days; Assigned to Arm(s): Amoxicillin-Clavulanate, 5 days
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Modified formula (MFGM-enriched formula with reduced energy and protein content) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Modified formula (MFGM-enriched formula with reduced energy and protein content); Assigned to Arm(s): 1
C: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice
D: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-invasive Chromosomal Examination of Trisomy
Brief Summary: The purpose of this blinded, multi-center, prospective, case-controlled study is to compare the Ariosa Harmony™ Prenatal Test for trisomy 21 detection with a standard first-trimester prenatal screening test consisting of serum screening (PAPP-A,free beta-hCG \[β-hCG\] or total hCG) and a nuchal translucency (NT) measurement (i.e. combined first trimester screening) in a general screened population.

The performance characteristics of these two test modalities will be assessed relative to the clinical reference standard of genetic analysis of the fetus or phenotypic characterization and genetic analysis of the newborn.


Options:
A: Arm Label: All-risk pregnant women; Type: N/A; Interventions: N/A
B: Arm Label: Chromosomal Abnormality; Type: N/A; Interventions: N/A | Arm Label: No Chromosomal Abnormality; Type: N/A; Interventions: N/A
C: Arm Label: Down syndrome; Type: N/A; Interventions: N/A
D: Arm Label: Case; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hyperinvasive Approach to out-of Hospital Cardiac Arrest Using Mechanical Chest Compression Device, Prehospital Intraarrest Cooling, Extracorporeal Life Support and Early Invasive Assessment Compared to Standard of Care. A Randomized Parallel Groups Comparative Study. "Prague OHCA Study"
Brief Summary: Prague out-of Hospital Cardiac Arrest (OHCA) study is a prospective randomized multicenter clinical study comparing use of prehospital intraarrest hypothermia, mechanical chest compression device, extracorporeal life support (ECLS) and early invasive investigation and treatment (coronary angiography/percutaneous coronary intervention \[PCI\]; pulmonary angiography/percutaneous embolectomy; aortography) in all patients with OHCA of presumed cardiac origin compared to standard of care. It is hypothesized, that above stated "hyperinvasive" approach might improve outcome of out-of hospital cardiac arrest victims.


Options:
A: Arm Label: RhinoChill; Type: EXPERIMENTAL; Interventions: Device: RhinoChill | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DEVICE; Name: RhinoChill; Assigned to Arm(s): RhinoChill | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Prehospital intra-nasal cooling with RhinoChill | Intervention Type: DEVICE; Name: Prehospital intra-nasal cooling with RhinoChill; Assigned to Arm(s): Intervention
C: Arm Label: Hyperinvasive arm; Type: EXPERIMENTAL; Interventions: Device: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS | Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS; Assigned to Arm(s): Hyperinvasive arm | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard arm
D: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The aim of this study is to evaluate the efficacy of myo-inositol in preventing gestational diabetes in high risk pregnant women.


Options:
A: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
C: Arm Label: Myo-inositol powder; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Myo-inositol soft gel capsules; Type: EXPERIMENTAL; Interventions: Dietary Supplement: inositol + folic acid | Arm Label: Folic acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol powder | Intervention Type: DIETARY_SUPPLEMENT; Name: inositol + folic acid; Assigned to Arm(s): Myo-inositol soft gel capsules | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic acid
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: C